Clinical forecasting in drug development

Nature Reviews Drug Discovery

Volumn 6, Issue 2, 2007, Pages 107-108

  Schachter, Asher D ^a   Ramoni, Marco F ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; DRUG;

ACCESS TO INFORMATION; ACCURACY; ARTICLE; BAYES THEOREM; BIOTECHNOLOGY; CLINICAL RESEARCH; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; FINANCIAL MANAGEMENT; FORECASTING; HEALTH CARE DELIVERY; METHODOLOGY; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; PROFIT; PUBLIC HEALTH; RHABDOMYOLYSIS; RISK REDUCTION; SIMULATION; VALIDATION PROCESS; CLINICAL TRIAL; ECONOMICS; HUMAN; THEORETICAL MODEL;

BAYES THEOREM; CLINICAL TRIALS; DRUG INDUSTRY; FORECASTING; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS;

EID: 33947594385     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2246     Document Type: Article

References (17)

1. DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
2. DiMasi, J. A. The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoeconomics 20 (Suppl. 3), 1-10 (2002).
3. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
4. Earl, J. What makes a good forecaster? Nature Rev. Drug Discov. 2, 83 (2003).
5. Booth, B. & Zemmel, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451-456 (2004).
6. Hunt, C.A., Guzy, S. & Weiner, D.L. A forecasting approach to accelerate drug development. Stat. Med. 17, 1725-1740 (1998).
7. Poland, B. & Wada, R. Combining drug-disease and economic modelling to inform drug development decisions. Drug Discov. Today 6, 1165-1170 (2001).
8. Rooney, K.F., Snoeck, E. & Watson, P.H. Modelling and simulation in clinical drug development. Drug Discov. Today 6, 802-806 (2001).
9. Chilcott, J., Brennan, A., Booth, A., Karnon, J. & Tappenden, P. The role of modelling in prioritising and planning clinical trials. Health Technol. Assess. 7, 1-125 (2003).
10. De Ridder, F. Predicting the outcome of phase III trials using phase II data: A case study of clinical trial simulation in late stage drug development. Basic Clin. Pharmacol. Toxicol. 96, 235-241 (2005).
11. Vastag, B. New clinical trials policy at FDA. Nature Biotechnol. 24, 1043 (2006).
12. Schachter, A.D., Ramoni, M.F., Baio, G., Roberts, T.G., Jr. & Finkelstein, S.N. Economic evaluation of a Bayesian model to predict late phase success of new chemical entities. Value Health (in the press).
13. The Pharmaceutical Research and Manufacturers of America (PhRMA). Principles on conduct of clinical trials and communication of clinical trial results. PhRMA web site [online], (2004).
14. Bouchie, A. Clinical trial data: To disclose or not to disclose? Nature Biotechnol. 24, 1058-1060 (2006).
15. Committee on the Assessment of the US Drug Safety System. The Future of Drug Safety: Promoting and Protecting the Health of the Public (IOM, Washington, DC, 2006).
16. Szarfman, A. et al. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25; 381-392 (2002).
17. Noren, G. N. et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat. Med. 25, 3740-3757 (2006).